Crown Bioscience has developed and validated a unique set of models for immuno-oncology called HuGEMM. “Up until now, the lack of models available to test the in vivo efficacy of new antibody-based immunotherapies and combination therapies has hindered the research process,” said Jean-Pierre Wery, president, Crown Bioscience. “With HuGEMM, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse ...